<DOC>
	<DOCNO>NCT00415350</DOCNO>
	<brief_summary>1 . SUMMARY Rationale : Patients bronchiectasis often experience low respiratory tract infection progression symptom decline quality life . Macrolides , show panbronchiolitis cystic fibrosis , may break weaken link infection inflammation result improvement symptom . Also number exacerbation may lower . Objective : A reduction number infective exacerbation improvement lung function AZT treatment primary objective . Secondary objective evaluate : symptom score , quality life , inflammatory parameter , bacterial colonisation , adverse event . Study design : Randomised double blind multicenter study Netherlands . Patients stratified colonisation P.aeruginosa . Study population : Patients bronchiectasis demonstrate high-resolution compute tomography ( HR-CT ) scan bronchography . Intervention : Patients receive Azithromycin 250mg ( p.o . ) daily placebo . Main study parameters/endpoints : Reduction number exacerbation , define increase symptom dyspnoea , cough , sputum production course prednisolone and/or antibiotic need . Change lung function parameter ( forced expiratory volume 1 second [ FEV1 ] , force vital capacity [ FVC ] ) measure spirometry primary endpoint . Nature extent burden risk associate participation , benefit group relatedness : The risk participate study low . Laboratory , radiographic examination , pulmonary function test commonly use diagnostic procedure outpatients visit exacerbation . Adverse effect maintenance treatment AZT usually mild mainly gastrointestinal . Sometimes rash abnormal liver function test observe . A good quality life probably beneficial effect long term treatment AZT . This achieved reduction respiratory non-respiratory symptom number exacerbation .</brief_summary>
	<brief_title>Bronchiectasis Long Term Azithromycin Treatment</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<criteria>Patients age 18 ≥ year Bronchiectasis diagnose plain bronchography high resolution computer tomography . Minimal 3 low respiratory tract infection ( LRTI ) treat oral/intravenous ( IV ) antibiotic year precede study inclusion . The presence chronic respiratory symptom cough , dyspnoea , expectoration sputum . At least one positive sputum culture precede year . Informed consent Previous ( ≥ 4 week ) prolong macrolide therapy . Pregnant lactating woman . Allergy macrolides . Intolerance macrolides . Liver disease ( alanine transaminase and/or aspartate transaminase level 2 time upper limit normal ) . Use antibiotic within 14 day screen . Use oral IV corticosteroid ( ≥ 30 mg prednisolone/daily ) within 30 day screen . Other research medication start 2 month prior inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bronchiectasis</keyword>
	<keyword>Macrolide</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Antibiotic prophylaxis</keyword>
	<keyword>Immunomodulation</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Lung function</keyword>
	<keyword>Sputum</keyword>
	<keyword>Bacterial colonization</keyword>
</DOC>